全文获取类型
收费全文 | 1094篇 |
免费 | 71篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 37篇 |
妇产科学 | 19篇 |
基础医学 | 133篇 |
口腔科学 | 25篇 |
临床医学 | 95篇 |
内科学 | 301篇 |
皮肤病学 | 17篇 |
神经病学 | 35篇 |
特种医学 | 12篇 |
外科学 | 165篇 |
综合类 | 27篇 |
一般理论 | 1篇 |
预防医学 | 74篇 |
眼科学 | 36篇 |
药学 | 54篇 |
中国医学 | 3篇 |
肿瘤学 | 131篇 |
出版年
2023年 | 7篇 |
2022年 | 22篇 |
2021年 | 39篇 |
2020年 | 25篇 |
2019年 | 31篇 |
2018年 | 34篇 |
2017年 | 23篇 |
2016年 | 28篇 |
2015年 | 31篇 |
2014年 | 50篇 |
2013年 | 58篇 |
2012年 | 101篇 |
2011年 | 78篇 |
2010年 | 50篇 |
2009年 | 40篇 |
2008年 | 66篇 |
2007年 | 63篇 |
2006年 | 71篇 |
2005年 | 50篇 |
2004年 | 42篇 |
2003年 | 47篇 |
2002年 | 40篇 |
2001年 | 17篇 |
2000年 | 8篇 |
1999年 | 11篇 |
1998年 | 7篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 10篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 10篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 4篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1940年 | 1篇 |
1933年 | 3篇 |
1930年 | 4篇 |
1929年 | 5篇 |
1928年 | 1篇 |
1921年 | 1篇 |
排序方式: 共有1169条查询结果,搜索用时 0 毫秒
21.
Visceral leishmaniasis: current status of control,diagnosis, and treatment,and a proposed research and development agenda 总被引:13,自引:0,他引:13
Guerin PJ Olliaro P Sundar S Boelaert M Croft SL Desjeux P Wasunna MK Bryceson AD 《The Lancet infectious diseases》2002,2(8):494-501
Visceral leishmaniasis is common in less developed countries, with an estimated 500000 new cases each year. Because of the diversity of epidemiological situations, no single diagnosis, treatment, or control will be suitable for all. Control measures through case finding, treatment, and vector control are seldom used, even where they could be useful. There is a place for a vaccine, and new imaginative approaches are needed. HIV co-infection is changing the epidemiology and presents problems for diagnosis and case management. Field diagnosis is difficult; simpler, less invasive tests are needed. Current treatments require long courses and parenteral administration, and most are expensive. Resistance is making the mainstay of treatment, agents based on pentavalent antimony, useless in northeastern India, where disease incidence is highest. Second-line drugs (pentamidine and amphotericin B) are limited by toxicity and availability, and newer formulations of amphotericin B are not affordable. The first effective oral drug, miltefosine, has been licensed in India, but the development of other drugs in clinical phases (paromomycin and sitamaquine) is slow. No novel compound is in the pipeline. Drug combinations must be developed to prevent drug resistance. Despite these urgent needs, research and development has been neglected, because a disease that mainly affects the poor ranks as a low priority in the private sector, and the public sector currently struggles to undertake the development of drugs and diagnostics in the absence of adequate funds and infrastructure. This article reviews the current situation and perspectives for diagnosis, treatment, and control of visceral leishmaniasis, and lists some priorities for research and development. 相似文献
22.
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma 总被引:1,自引:0,他引:1
Rangaswamy Govindarajan Sundar Jagannath James T. Flick David H. Vesole Jeffrey Sawyer Bart Barlogie & Guido Tricot 《British journal of haematology》1996,95(2):349-353
Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) have been reported after autologous transplantation (AT) for lymphoma. It is not clear whether myeloablative therapy used in conjunction with autologous transplantation contributes to the development of MDS/AML or whether the conventional chemotherapy preceding the transplant, and administered over a prolonged period, causes these secondary malignancies. To address this issue, we examined 188 patients with multiple myeloma (MM) who had received AT. 71 patients with no more than one cycle of standard chemotherapy were enrolled in our Total Therapy program, designed to avoid exposure to alkylating agents prior to peripheral blood stem cell mobilization (group 1). The median duration of pre-transplant therapy in group 1 was 7.6 months and significantly shorter than the 24 months of 117 patients (group 2) with more prolonged conventional therapy ( P = 0.0001). All seven patients developing MDS post-transplantation belonged to group 2 ( P = 0.02); the median durations from initial therapy and first transplant were 66 months (range 38–86) and 24 months (range 9–39), respectively. Our findings provide evidence that prolonged standard-dose alkylating agent therapy prior to transplantation, rather than autotransplant-supported myeloablative treatment, is associated with development of MDS/AML. Stem cell damaging alkylator treatment should be avoided, not to compromise PBSC collection, but also to reduce the risk of treatment-related MDS/AML. 相似文献
23.
Arpita Kulshrestha Vasundhra Bhandari Rupkatha Mukhopadhyay V. Ramesh Shyam Sundar Louis Maes Jean Claude Dujardin Syamal Roy Poonam Salotra 《Parasitology research》2013,112(2):825-828
Simple, cost-effective approach for routine surveillance of parasite susceptibility to antileishmanial drug miltefosine (MIL) is highly desirable for controlling emergence of drug resistance in visceral leishmaniasis (VL). We validated a simple resazurin-based fluorimetric assay using promastigotes to track natural MIL tolerance in Leishmania donovani parasites from VL cases (n?=?17) against standard amastigote assay, in two different labs in India. The inter-stage MIL susceptibility correlated strongly (r?=?0.70, p?=?0.0018) using J774.A.1 macrophage cell line-based amastigote assay and fluorescence-based resazurin assay for promastigotes. Investigation of inter-stage MIL susceptibility for the same set of clinical isolates in another lab also showed a strong correlation (r?=?0.72, p?=?0.0012) using mouse peritoneal macrophages for amastigote assay and resazurin-based alamar blue assay for promastigotes. Additionally, parasites from post-kala-azar dermal leishmaniasis (PKDL) lesions (n?=?7, r?=?0.78, p?=?0.046) and MIL-induced parasites (r?=?0.92, p?=?0.0001; n?=?3) also exhibited a strongly correlated inter-stage miltefosine susceptibility. Thus, our results support the utility of resazurin assay as a simplified biological tool for MIL susceptibility monitoring in clinical isolates from MIL-treated VL/PKDL patients. 相似文献
24.
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma 总被引:9,自引:1,他引:9 下载免费PDF全文
Richardson PG Barlogie B Berenson J Singhal S Jagannath S Irwin D Rajkumar SV Hideshima T Xiao H Esseltine D Schenkein D Anderson KC;SUMMIT Investigators 《Blood》2005,106(9):2977-2981
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and was not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or beta2-microglobulin. By multivariate analysis, factors associated with lower response were being age 65 or older versus younger than 65 (19% vs 32%; P < .05) and plasma-cell infiltration in bone marrow greater than 50% versus 50% or less (20% vs 35%; P < .05). Factors that may be indicative of tumor burden (bone marrow plasma-cell infiltration greater than 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated beta2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study. 相似文献
25.
26.
Desikan R Barlogie B Sethi R Toor A Spoon D Angtuaco E Vanhemert R VijayaGopal A Singhal S Mehta J Jagannath S Munshi N Zangari M Fassas A Tricot G Anaissie E 《British journal of haematology》2003,120(6):1047-1050
Bone pain, especially back pain, is a common presenting feature of myeloma patients. We report three multiple myeloma patients with exacerbations of back pain and referred shoulder pain resulting from vertebral infections. Two patients were treated with surgery, and one patient had computerized tomography-guided percutaneous needle aspiration for diagnostic purposes. All three patients received a prolonged course of antibiotics. Vertebral infection resolved with this treatment in all three patients without any recurrence. Previous dexamethasone therapy, together with an episode of bacteraemia, appears to be a predisposing factor for vertebral infection. Magnetic resonance imaging enabled the diagnosis in all three patients. 相似文献
27.
Abraham Samuel Babu Kushal Madan Sundar Kumar Veluswamy Rahul Mehra Arun G. Maiya 《Progress in cardiovascular diseases》2014
Worksite health and wellness (WH&W) are gaining popularity in targeting cardiovascular (CV) risk factors among various industries. India is a large country with a larger workforce in the unorganized sector than the organized sector. This imbalance creates numerous challenges and barriers to implementation of WH&W programs in India. Large scale surveys have identified various CV risk factors across various industries. However, there is scarcity of published studies focusing on the effects of WH&W programs in India. This paper will highlight: 1) the current trend of CV risk factors across the industrial community, 2) the existing models of delivery for WH&W in India and their barriers, and 3) a concise evidence based review of various WH&W interventions in India. 相似文献
28.
29.
30.
Tomato immune receptor Ve1 recognizes effector of multiple fungal pathogens uncovered by genome and RNA sequencing 总被引:5,自引:0,他引:5